Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.

Oncology reports - 1 Sept 2013

Yamamoto Yuki, Fukuda Kazumasa, Fuchimoto Yasushi, Matsuzaki Yumi, Saikawa Yoshiro, Kitagawa Yuko, Morikawa Yasuhide, Kuroda Tatsuo

Abstract excerpt

Overexpression of human epidermal growth factor receptor (EGFR) has been detected in various tumors and is associated with poor outcomes. Combination treatment regimens with EGFR-targeting and cytotoxic agents are a potential therapeutic option for rhabdomyosarcoma (RMS) with EGFR amplification. We investigated the effects of combination treatment with actinomycin D and the EGFR-targeting agent cetuximab in 4 RMS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dactinomycin

Share to Drug Synergism

Share to Gene Amplification

Share to In Vitro Techniques

Share to ras Proteins

Share to Rhabdomyosarcoma

Source

Identifiers

PMID: 23828214
DOI: 10.3892/or.2013.2588

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.PMID 23828214Read ↗

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma ModelsSemantic proximity Read ↗

NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3Kα.Semantic proximity Read ↗

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapySemantic proximity Read ↗

Efficacy of the MEK1/2 inhibitor trametinib in combination with clinically-investigated γ-secretase inhibitors in rhabdomyosarcomaSemantic proximity Read ↗

EGFR Alterations Influence the Cetuximab Treatment Response and c-MET Tyrosine-Kinase Inhibitor Sensitivity in Experimental Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.Semantic proximity Read ↗

An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.Semantic proximity Read ↗

Combination effect of cetuximab with radiation in colorectal cancer cells.Semantic proximity Read ↗

EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.Semantic proximity Read ↗

Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cellsSemantic proximity Read ↗

Hedgehog Inhibitors in Rhabdomyosarcoma: A Comparison of Four Compounds and Responsiveness of Four Cell LinesSemantic proximity Read ↗

Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.